No Data
No Data
Tianjin Development (00882.HK) subsidiary intends to sell 24.65% equity of Tianjin Tianbian Pharmaceutical for 120 million yuan.
On June 28, Gelonhui reported that Tianjin Dev (00882.HK) announced the sale of 24.65% equity in Tianjin Tianbian Pharmaceutical Co., Ltd. On June 28, 2024, Tianjin Lisheng Pharmaceutical and the final winning bidder, Grandpharma (China), entered into a property transaction contract for the sale of the shares at a total price of 120 million yuan. After the completion of the sale, the Group will no longer hold any equity in Tianjin Tianbian. Tianjin Tianbian is a limited liability company established in China, mainly engaged in the production, processing, sales of Chinese and Western medicines, chemical drugs, active pharmaceutical ingredients, trial drugs, biological pharmaceuticals, related services, and the provision of medical information consulting.
Express News | Tianjin Development - Deal for RMB120.3 Mln
Express News | Tianjin Development Holdings Ltd - Disposal of 24.65% Equity Interest in Tianjin Tanabe Seiyaku Co., Ltd
Lisheng Pharmaceutical Avails of 92-Day Structured Deposit Product
Tianjin Dev (00882.HK) subscribed to 150 million yuan of wealth management products.
On June 11, Gelunhui reported that Tianjin Dev (00882.HK) announced that on June 11, 2024, Tianjin Lisheng Pharmaceutical and CBHB signed a second CBHB Wealth Management Agreement to subscribe for structured deposits with a principal amount of RMB 150 million.
Tianjin Dev (00882): Tianjin Lisheng Pharmaceutical subscribes to a total principal amount of 210 million yuan of structured deposits.
Tianjin DEV (00882) announced that on April 30, 2024, its indirectly non-wholly subsidiary Tianjin Lisheng Pharmaceutical and CBHB signed the first CBHB wealth management agreement to subscribe to structured deposits with a principal amount of RMB 60 million. On June 11, 2024, Lisheng Pharmaceutical and CBHB signed the second CBHB wealth management agreement to subscribe to structured deposits with a principal amount of RMB 150 million.
No Data